Safinamide Mesylate

Names

[ CAS No. ]:
202825-46-5

[ Name ]:
Safinamide Mesylate

[Synonym ]:
(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide
N-{4-[(3-Fluorobenzyl)oxy]benzyl}-L-alaninamide methanesulfonate (1:1)
Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1)
(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide,methanesulfonic acid
PNU-151774E,NW-1015
Safinamide mesylate
(S)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide,methanesulfonate
(S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide
FCE-28073(R-isomer),PNU-151774E,NW-1015

Biological Activity

[Description]:

Safinamide mesylate mesylate (FCE 26743 mesylate; EMD 1195686 mesylate) is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

[Related Catalog]:

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase

Research Areas >> Neurological Disease

[Target]

MAO-B:98 nM (IC50)

MAO-A:580 nM (IC50)

[In Vitro]

Safinamide mesylate (1-300 µM) reduces the amplitude of the peak sodium currents in a concentration-dependent manner. When currents are stimulated to a Vtest of +10 mV from a Vh of -110 mV, the IC50 value was 262 µM. When the holding potential is depolarized to -53 mV, the inhibitory effect of Safinamide mesylate with a lower IC50 value (8 µM) in rat cortical neurons[1].

[In Vivo]

Safinamide mesylate (intraperitoneal injection; 90 mg/kg; once daily; 14 days) treatment prior to MCAO significantly ameliorates MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impairs expression of tight junction protein occludin and ZO-1 in mice[3]. Safinamide mesylate (intraperitoneal injection; 5 mg/kg, 15 mg/kg and 30 mg/kg) dose dependently inhibits the veratridine-induced GABA release and Glu release in vivo. At the dose 30 mg/kg, Safinamide mesylate prevents the effect of veratridine both on Glu (treatment F1,8=1.31; time×treatment interaction F8,64=2.4) and GABA (treatment F1,8=4.04; time F8,64=3.76, time×treatment interaction F8,64=2.83) release. Safinamide mesylate causes a slight, albeit not significant, reduction of veratridine-stimulated Glu release at 0.5 mg/kg and full inhibition at 5 and 15 mg/kg in rat[3].

[References]

[1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916.

[2]. C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23.

[3]. Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364(2):198-206.

Chemical & Physical Properties

[ Boiling Point ]:
476.7ºC at 760 mmHg

[ Melting Point ]:
210° (dec)

[ Molecular Formula ]:
C₁₈H₂₃FN₂O₅S

[ Molecular Weight ]:
398.449

[ Flash Point ]:
242.1ºC

[ Exact Mass ]:
398.131165

[ PSA ]:
127.10000

[ LogP ]:
4.04410

[ Vapour Pressure ]:
2.98E-09mmHg at 25°C

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS05, GHS06, GHS09

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301-H318-H400

[ Precautionary Statements ]:
P273-P280-P301 + P310-P305 + P351 + P338

[ Hazard Codes ]:
C

[ RIDADR ]:
UN 2811 6.1 / PGIII

[ HS Code ]:
2924299090

Customs

[ HS Code ]: 2924299090

[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%